Ovarian Cancer Trial, Recruiting NCT05030805 Sponsor: University Hospital, Strasbourg, France Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT05030805
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged 18 or older
  • People who have been diagnosed with ovarian cancer, confirmed through a laboratory tissue analysis
  • People who had surgery in the gynaecology department at Strasbourg University Hospital between 2021 and 2024
  • People who have agreed to take part in the trial and to have biological samples collected as part of it

Who may not be able to join:

  • People who have a chronic inflammatory condition, such as lupus, rheumatoid arthritis, or chronic inflammatory bowel disease
  • People who have previously received immunotherapy treatment (such as anti-PDL1 medicines)
  • People who have previously had their appendix removed for a reason unrelated to this condition
  • People for whom it is not possible to provide proper informed consent — for example, due to being in an emergency situation, having difficulty understanding, facing a language barrier, or having reduced cognitive ability
  • People who are under legal protection, guardianship, or supervised legal protection arrangements
  • People who are pregnant or breastfeeding
  • People who are currently deprived of their liberty by a court or administrative decision
  • People who are currently receiving involuntary psychiatric care

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 3 88 12 74 55

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 May 2022
Est. completion
1 April 2030

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Cellular heterogeneity in ovarian cancer

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov